Role of Cholinergic Signaling in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.
Abstract
Acetylcholine, a neurotransmitter secreted by cholinergic neurons, is involved in signal transduction related to memory and learning ability. Alzheimer’s disease (AD), a progressive and commonly diagnosed neurodegenerative disease, is characterized by memory and cognitive decline and behavioral disorders. The pathogenesis of AD is complex and remains unclear, being affected by various factors. The cholinergic hypothesis is the earliest theory about the pathogenesis of AD. Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD. In addition, abnormal central cholinergic changes can also induce abnormal phosphorylation of ttau protein, nerve cell inflammation, cell apoptosis, and other pathological phenomena, but the exact mechanism of action is still unclear. Due to the complex and unclear pathogenesis, effective methods to prevent and treat AD are unavailable, and research to explore novel therapeutic drugs is various and active in the world. This review summaries the role of cholinergic signaling and the correlation between the cholinergic signaling pathway with other risk factors in AD and provides the latest research about the efficient therapeutic drugs and treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation AChEIs, including donepezil (4), rivastigmine (5), galantamine (6), are more selective. They exhibited fewer side effects or improved pharmacokinetic profiles, establishing them as first-line drugs for AD.98,400”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is a progressive neurodegenerative disorder and the leading cause of dementia among older adults, characterized by a gradual decline in cognitive function, memory loss, and behavioral changes, ultimately leading to complete dependence on caregivers [7].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, neurons of the nucleus basalis of Meynert (NBM) are particularly vulnerable, and their degeneration leads to profound reductions in choline acetyltransferase (ChAT) activity within projection areas such as the cerebral cortex and hippocampus, regions essential for learning, memory, and attention [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This hypothesis suggests that a reduction in the synthesis and release of ACh impairs its physiological functions, which are critical for learning, memory, and other cognitive processes.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The cholinergic hypothesis, one of the earliest and most influential theories of AD, proposed that the characteristic cognitive deficits of the disorder arise primarily from degeneration of cholinergic neurons in the basal forebrain [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hafez, H. S., Ghareeb, D. A., Saleh, S. R., Abady, M. M., Demellawy, M. E., Hussien, H. M., & Abdel-Monem, N. M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4690-x · Cited by 85
RetractedSemwal, B. C., & Garabadu, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08615-1 · Cited by 9 · cited 2×
“Aβ can induce mitochondrial toxicity in the brain, resulting in cognitive dysfunction [5].”
BackgroundRetractedNEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311 · cited 1×
“According to clinical data in recent years, the brains of patients with AD show severe neurodegeneration and reduction of cholinergic neurons and a severe deficiency of Ach; acetylcholine transferase activity is significantly decreased, which further illustrates the damage to the cholinergic system in patients with AD…”
BackgroundEfficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312 · cited 1×
“AD is a major cause of dementia which is a common disease among the elderly, starting with an irreversible decline in episodic memory and then a more general decline in overall cognitive ability [2,3].”
BackgroundLiu, Y., Zhang, Y., Zheng, X., Fang, T., Yang, X., Luo, X., Guo, A., Newell, K. A., Huang, X.-F., & Yu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1141-5 · Cited by 285 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
BackgroundLuo, H., Xiang, Y., Qu, X., Liu, H., Liu, C., Li, G., Han, L., & Qin, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00395 · Cited by 264 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
Background
Research works printed but not linked: 1
- Yu, 2019, Protective roles of isoastilbin against Alzheimer’s disease via Nrf2mediated antioxidation and antiapoptosis, Int. J. Mol. Med., 43, 1406
Cited by
Items 201–300 of 1,000
Thakur, A., Rana, M., Vanjani, S., Liou, K.-C., Taliyan, R., Nepali, K., & Yang, C. (2026) · Medicinal Research Reviews · doi:10.1002/med.70047 · Cited by 12
Bychkov, M. L., Isaev, A. B., Andreev-Andrievskiy, A. A., Petrov, K. A., Paramonov, A. S., Kirpichnikov, M. P., & Lyukmanova, E. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914852 · Cited by 12
“Besides amyloidosis, cholinergic system dysfunction is also characteristic for AD progression [49,50]; however, the implication of the cholinergic system in AD pathology in the cerebellum has not been previously studied.”
BackgroundBoiangiu, R. Ş., Brinza, I., Honceriu, I., Mihăşan, M., & Hriţcu, L. (2023) · Biomolecules · doi:10.3390/biom14010023 · Cited by 12
“The cholinergic hypothesis of AD states that a reduction in ACh synthesis is the main cause of the disease [200,201].”
BackgroundKadian, M., Saini, N., Khera, A., & Kumar, A. (2024) · Inflammopharmacology · doi:10.1007/s10787-023-01413-8 · Cited by 12
“Further, in AD, patients commonly exhibit acetylcholine deficiency and impaired cholinergic signal transduction (Chen et al. 2022), and AChE activity serves as an indicator of cholinergic function (Javed et al. 2015).”
Borikar, S. P., Sonawane, D. S., Tapre, D. N., & Jain, S. P. (2024) · International Journal of Neuroscience · doi:10.1080/00207454.2024.2342973 · Cited by 12
“In addition to these neuropathological features, there is significant disruptions in several neurotransmitter systems, particularly in cholinergic neuro-transmission, which leads to cognitive impairments [4].”
Stanciu, G. D., Ababei, D. C., Solcan, C., Urîtu, C. M., Crăciun, V. C., Pricope, C. V., Szilagyi, A., & Tamba, B.-I. (2024) · Pharmaceuticals · doi:10.3390/ph17040530 · Cited by 12
“Conversely, endocannabinoids have been shown to exert regulatory influence on cholinergic signaling pathways, highlighting the bidirectional communication within the endocannabinoidome [20,21].”
BackgroundPathophysiological and therapeutic implications of neuropeptide S system in neurological disorders
Shirasath, K. R., Patil, V. K., Awathale, S. N., Goyal, S. N., & Nakhate, K. T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171167 · Cited by 11
Zhang, J., Cui, X., Zhao, S., Chang, Z., Zhang, J., Chen, Y., Liu, J., Sun, G., Wang, Y., & Liu, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1342121 · Cited by 11
Gayathiri, E., Prakash, P., Pratheep, T., Chaudhari, S. Y., & Priyadharshini, S. D. (2024) · The Microbe · doi:10.1016/j.microb.2024.100150 · Cited by 11
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization
Osse, A. M. L., Kinney, J. W., & Cummings, J. L. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70050 · Cited by 11
Szala‐Rycaj, J., Zagaja, M. P., Szewczyk, A., Polak, J., & Andres‐Mach, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080635 · Cited by 12
“Impaired learning and memory functions associated with aging are primarily attributed to cholinergic dysfunction, including impaired acetylcholine (ACh) release and increased acetylcholinesterase (AChE) activity in CNS neurons [6,7].”
Kaya, B., Çevik, U. A., Çiftci, B., Necip, A., Işık, M., Ay, E. N., Yur, S., Özkay, Y., Beydemir, Ş., & Kaplancıklı, Z. A. (2025) · ACS Omega · doi:10.1021/acsomega.5c01055 · Cited by 11
Ainyanbhor, I. E., Edo, G. I., Ali, A. B. M., Akpoghelie, P. O., Akpo, M. O., Yousif, E. A., Owheruo, J. O., Igbuku, U. A., Obayomi, O. V., Essaghah, A. E. A., et al. (2025) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2025.100066 · Cited by 11
Simões, J. L. B., Sobierai, L. D., Leal, I. F., dos Santos, M. V. R., Coiado, J. V., & Bagatini, M. D. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.12.007 · Cited by 11
Central Nicotinic and Muscarinic Receptors in Health and Disease
Tizabi, Y., Getachew, B., Tsytsarev, V., Csoka, A. B., Copeland, R., & Heinbockel, T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.112447 · Cited by 11
Anadozie, S. O., Aduma, A. U., & Adewale, O. B. (2023) · Vegetos · doi:10.1007/s42535-023-00760-9 · Cited by 11
“Free form of copper is potentially damaging; therefore, its absorption and excretion are tightly regulated in the body (Chen et al. 2022b).”
Alzheimer's Disease and Suicide: An Integrative Literature Review
Rodrigues, J. F. R., Rodrigues, L. P., & Filho, G. M. D. A. (2023) · Current Alzheimer Research · doi:10.2174/0115672050292472240216052614 · Cited by 11
The Greater Omentum: Multifaceted Interactions in Neurological Recovery and Disease Progression
Li, X., Ding, Y., Haddad, Y. W., & Geng, X. (2024) · Aging and Disease · doi:10.14336/ad.2024.0213 · Cited by 11
Mahmoud, O. A., Ayoub, I. M., Eldahshan, O. A., & Singab, A. N. B. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04443-z · Cited by 11
“Its decrease has been related to AD [48].”
BackgroundLoori, S., Pourtaher, H., Mehranpour, A., Hasaninejad, A., Eftekharian, M., & Iraji, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-64179-1 · Cited by 11
“As a result, enhancing ACh levels provides modest effects on AD symptoms 7,8 .”
Koppula, S., Wankhede, N. L., Sammeta, S. S., Shende, P. V., Pawar, R. S., Chimthanawala, N. M. A., Umare, M. D., Taksande, B. G., Upaganlawar, A. B., Umekar, M. J., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102389 · Cited by 11
Gürsoy, Ş., Satici, D., Kuzu, B., Türkmenoğlu, B., Dilek, E., & Algül, Ö. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202400918 · Cited by 11
Salahuddin, M., Abdel‐Wareth, A. A. A., Rashwan, A. K., Hiramatsu, K., Fulzele, S., & Lohakare, J. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.105096 · Cited by 11
Conceição, M., Filippo, L. D. D., Duarte, J. L., Beserra, F. P., Gremião, M. P. D., & Chorilli, M. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100894 · Cited by 11
Promising protective potential of MiR-103a-3p against polystyrene microplastic neurotoxicity in rats
Mohammadi, L., Baluchnejadmojarad, T., Goudarzi, M., Khodashenas, V., Khoshravesh, R., & Roghani, M. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1560980 · Cited by 11
Xie, Y., Liu, L., Zheng, J., Shi, K., Ai, W., Zhang, X., Wang, P., Lan, Z., & Chen, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116400 · Cited by 11
Sobczuk, J., Paczkowska, K., Andrusiów, S., Bolanowski, M., & Daroszewski, J. (2024) · Biomolecules · doi:10.3390/biom14080918 · Cited by 10
“Impairment of the cholinergic system, which is particularly involved in cognitive processes, especially memory, also plays a significant role in the Alzheimer disease pathogenesis [23].”
Isatin derived morpholine and piperazine derivatives as acetylcholinesterase inhibitors
Thomas, R. R., Trisciuzzi, D., Sudevan, S. T., Gambacorta, N., Catto, M., Kumar, S., Abdelgawad, M. A., El-Ghorab, A. H., Selim, S., Ghoneim, M. M., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140503 · Cited by 10
Cornford, N., & Charnley, M. (2025) · Nutrition Research Reviews · doi:10.1017/s0954422425000058 · Cited by 10
Udi, O. A., Oyovwi, M. O., & Adeogun, A. E. (2025) · Discover Plants. · doi:10.1007/s44372-025-00127-1 · Cited by 10
“By inhibiting the breakdown of acetylcholine [101] gratissimum can help maintain optimal levels of this neurotransmitter, thereby improving cognitive performance [63].”
Ganzoni, R. L. Z., Bournons, S. S., Carreira, E. M., Bundel, D. D., & Smolders, I. J. (2025) · Medicinal Research Reviews · doi:10.1002/med.22105 · Cited by 10
Aloui, M., fadili, M. E., Mujwar, S., Er-rajy, M., Abuelizz, H. A., Er-Rahmani, S., Zarougui, S., & Elhallaoui, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-98182-x · Cited by 10
Liu, W., Li, Y., Qin, W., Wang, X., Li, W., Li, Y., Initiative, A. D. N., & Jia, J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70193 · Cited by 10
Chen, Y., Li, J., Zhang, S., Zhao, Y., Gao, D., & Xu, G. (2025) · Die Naturwissenschaften · doi:10.1007/s00114-025-01997-x · Cited by 10
“The level of lipid peroxidation is a common indicator to evaluate the degree of aging (Chen et al. 2022), and MDA is an important indicator to measure the level of lipid peroxidation(Hayes et al. 2020).”
Guan, Q., Cao, Y., Zhang, Y., Zhou, B., Wang, J., Baranenko, D., Cifuentes, A., Ibañez, E., Yuan, C., & Lu, W. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.105177 · Cited by 10
The Role of Bacopa monnieri in Alzheimer’s Disease: Mechanisms and Potential Clinical Use—A Review
Wiciński, M., Fajkiel-Madajczyk, A., Wójcicki, J., Ozorowski, M., & Szambelan, M. (2025) · Nutrients · doi:10.3390/nu17223538 · Cited by 10
“Loss of cognitive functions dependent on cholinergic conduction was one of the earliest hypotheses of AD [14].”
Challenges and Opportunities of Drug Delivery for Treatment of Alzheimer’s Disease
El-Fattah, M. A. A. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-025-03316-z · Cited by 10
Mesenchymal Stem Cell-Based Therapies Applied in Neurological Diseases: A Systematic Review
Trabulo, A., Sousa, P., Alvites, R., & Maurício, A. C. (2026) · Biomedicines · doi:10.3390/biomedicines14020475 · Cited by 10
“Degeneration primarily affects hippocampal and cortical neurons, including glutamatergic and cholinergic populations, leading to memory loss and cognitive decline (Figure 3) [34,35].”
Aljabri, M., Alharbi, K., & Alonazi, M. A. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103815 · Cited by 10
Youssef, S., Custódio, L. M. B., Rodrigues, M. J., Pereira, C. G., Calhelha, R. C., Jekő, J., Cziáky, Z., & Hamed, K. B. (2023) · Plants · doi:10.3390/plants12193391 · Cited by 10
“especially at the latter stages of the disease, where the brain has a deficit of ACh [24,30,31].”
BackgroundInfluentialVanillin derivatives as antiamnesic agents in scopolamine-induced memory impairment in mice
Gul, Q., Karim, N., Shoaib, M., Zahoor, M., Rahman, M. U., Bilal, H., Ullah, R., & Alotaibi, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26657 · Cited by 10
“Central cholinergic system is considered to be the most important neurotransmitter involved in regulation of cognitive functions [47].”
BackgroundResultBen‐Azu, B., Oghorodi, A. M., Oritsemuelebi, B., & Chidebe, E. O. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.112517 · Cited by 10
Tutuş, B., Kaya, A. Z., Baz, Y., Evren, A. E., Sağlık, B. N., & Yurttaş, L. (2024) · Drug Development Research · doi:10.1002/ddr.22214 · Cited by 10
“The cholinergic hypothesis proposed that Alzheimer is caused by a lack of a key neurotransmitter called acetylcholine (ACh) in the neuronal gaps (Chen et al., 2022; Walczak ‐ Nowicka & Herbet, 2021).”
BackgroundŠanda, P., Hlinka, J., van den Berg, M., Škoch, A., Bazhenov, M., Keliris, G. A., & Krishnan, G. P. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012099 · Cited by 10
Coffee and Alzheimer's disease
Mirzaei, F., Agbaria, L., Bhatnagar, K., Sirimanne, N., A'amar, N. O., Jindal, V., Thilagendra, A. G., & Raba, F. T. (2024) · Progress in brain research · doi:10.1016/bs.pbr.2024.06.002 · Cited by 10
Shirvani, M., Nouri, F., Sarihi, A., Habibi, P., & Mohammadi, M. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01400-y · Cited by 10
“Due to the signi fi cant role of cholinergic activities in memory and cognitive function, the development of cholinergic agonists and acetylcholinesterase (AChE) inhibitors have been conducted to treat mild to moderate AD [6, 7].”
Anti-Amnesic Effect of Agastache rugosa on Scopolamine-Induced Memory Impairment in Mice
Kang, S., Lee, N., Jung, B., Jeong, H., Moon, C., Park, S., Yun, S. P., Yim, T., Oh, J. M., Kim, J.-W., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17091173 · Cited by 10
“The mice were housed in a controlled environment with a temperature range of 23 ◦ C ± 2 ◦ C, a relative humidity of 50% ± 5%, an artificial lighting from 08:00 to 20:00 and an air exchange rate of 13–18 cycles per hour.”
MethodMast, N., Li, Y., & Pikuleva, I. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147669 · Cited by 10
“This is a new and important insight into the beneficial treatment effect as the brain Ach levels are decreased in AD due to selective degeneration of cholinergic neurons [34].”
BackgroundMurayama, M. A. (2023) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.22-0164 · Cited by 10
“The cholinergic hypothesis is one of the major hypotheses addressing the development of AD [24].”
BackgroundRodriguez, J. J., Gardenal, E., Zallo, F., Arrúe, A., Cabot, J., & Busquets, X. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.152131 · Cited by 9
Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes
Pyun, J., Park, Y. H., Kang, M. J., & Kim, S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01580-y · Cited by 9
Unveiling the role of Na⁺/K⁺-ATPase pump: neurodegenerative mechanisms and therapeutic horizons
Sidhu, R. K., Maparu, K., Singh, S., & Aran, K. R. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00717-6 · Cited by 9
Russo, A. P., Pastorello, Y., Dénes, L., Brînzaniuc, K., Krupiński, J., & SLEVIN, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136237 · Cited by 9
“This leads to a significant reduction in cortical and hippocampal cholinergic supply [29,30].”
Youssef, B., Ibrahim, E. A., Moselhy, S. S., ElShebiney, S. A., & ELabd, W. K. (2025) · Discover Nano · doi:10.1186/s11671-025-04356-x · Cited by 9
Çimentepe, M., Ünver, H., Necip, A., & Yıldırım, M. (2025) · Polyhedron · doi:10.1016/j.poly.2025.117861 · Cited by 9
Makkapati, M., Ramesha, G. B., Krishna, K. L., Ambika, M. S., Nadig, A. P. R., Pathak, S., & Jalawadi, P. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150226 · Cited by 9
McDonald, A. J. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25318 · Cited by 9
Implications of liquid-liquid phase separation and ferroptosis in Alzheimer's disease
Wang, F., Chen, Z., Zhou, Q., Sun, Q., Zheng, N., Chen, Z., Lin, J., Li, B., & Li, L. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110083 · Cited by 9
Self-citationPakaprot, N., Khamphaya, T., Kwankaew, P., Ninsuwan, S., Laisunthad, S., Thonoi, K., & Kuraeiad, S. (2024) · Veterinary World · doi:10.14202/vetworld.2024.1972-1982 · Cited by 9
Current pharmacophore based approaches for the development of new anti-Alzheimer’s agents
Sharma, P., Sharma, S., YADAV, Y. R., Shukla, P., & Sagar, R. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117926 · Cited by 9
Boosting Acetylcholine Signaling by Cannabidiol in a Murine Model of Alzheimer’s Disease
Khodadadi, H., Salles, É. L., Naeini, S. E., Bhandari, B., Rogers, H. M., Gouron, J., Meeks, W., Terry, A. V., Pillai, A., Yu, J. C.-K., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111764 · Cited by 9
Owumi, S. E., Chimezie, J., Emmanuel, P. D., Okeibuno, A. C., & Owoeye, O. (2024) · BMC Neuroscience · doi:10.1186/s12868-024-00922-8 · Cited by 9
Chik, M. W., Affandi, M. M. R. M. M., Hazalin, N. A. M. N., & Singh, G. K. S. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01560-7 · Cited by 10
“Therefore, restoring acetylcholine levels is important for mitigating AD symptoms (Chen et al. 2022).”
Kim, J.-E., Min, K.-S., Go, J., Park, H., Choi, Y., Lee, I.-B., Shin, J., Cho, H., Kim, H., Hwang, D. Y., et al. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13496 · Cited by 9
Mechanistic insight unrevealing the potential of Diadzein in ameliorating the Alzheimer’s disease
Diksha Dalal, L. S., Singh, L., & Singh, A. (2024) · Frontiers in Health Informatics · Cited by 9
Lee, J., Lee, S., Ji, H. W., Ji, H. W., Pyeon, M., Moon, M., Yun, J., Lee, J., & Sohn, S.-O. (2023) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-023-00732-z · Cited by 9
“Oxidative stress damage is also considered a factor in aging and neurodegenerative diseases (Liguori et al. 2018; Chen et al. 2022).”
Olasehinde, T. A., Ekundayo, T. C., Okaiyeto, K., & Olaniran, A. O. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01101-z · Cited by 9
Volatile oil of Acori tatarinowii rhizoma: potential candidate drugs for mitigating dementia
Bu, Y., Li, S., Ye, T., Wang, Y., Song, M., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1552801 · Cited by 8
Karakaya, A., Kaya, B., Yıldız, M. T., Erçetin, T., & Çevik, U. A. (2025) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426507.2025.2508322 · Cited by 8
Sharma, A., Kumar, P., Islam, A., Bhardwaj, M., Kumar, V., & Prakash, H. (2025) · Toxicology in Vitro · doi:10.1016/j.tiv.2025.106110 · Cited by 8
Asadi, K., Radha, K., Satarker, S., & Gurram, P. C. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05264-y · Cited by 8
Advancing Care in Alzheimer’s Disease: Current Treatments and Their Impact on Quality of Life
Yashaeva, L., Montoya, M., Joshi, J., Stephens, A., McNulty, O., & Kaur, G. (2025) · Cureus · doi:10.7759/cureus.90527 · Cited by 8
“Although AChE inhibitors do not prevent the progression of AD, they have been proven to be effective at alleviating symptoms of mild to moderate AD [25].”
InfluentialMolecular mechanisms underlying obesity-induced memory dysfunction: a comprehensive narrative review
Golkar, A., Razazpour, F., Dalfardi, M., & Baghcheghi, Y. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.115119 · Cited by 8
Therapeutic and Diagnostic Roles of MSC‐Derived Exosomes in Alzheimer's Disease
Patil, V. S., Parekh, B. K., Sharma, A., Farah, H., Renuka Jyothi, S., Mishra, S. S., Nanda, A., Al-Hasnaawei, S., & Kumar‐Mishra, M. (2025) · Brain and Behavior · doi:10.1002/brb3.71112 · Cited by 8
Nath, R., Ashique, S., Nehra, B., Debnath, I., Ghosh, S., Chawla, P. A., Al-Salem, F. M., Yasmin, S., Hussain, M. S., Das, L., et al. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11499-1 · Cited by 8
Alım, Z., & Demir, Y. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05347-0 · Cited by 8
“This leads to reduced acetylcholine (ACh) levels, particularly in brain regions associated with memory and cognitive functions (Chen et al. 2022; Demir et al. 2025).”
Khalifa, M. K. A., Abdel-Sattar, S. A., Amin, O. M., Kohaf, N. A., Zaky, H. S., El-Fattah, M. A. A., Mohammed, K. H. A., Badawi, N. M., Mansoor, I., & Eassa, H. A. (2023) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-023-00494-8 · Cited by 8
“More specifically, it binds to the enzyme presenilin-1 and promotes its expression, thereby elevating Aβ level and accelerating cognitive dysfunction [48].”
Salehi, A., Zolfaghari, B., Aghaei, M., Sirous, H., Sadeghi, M., Gholami, M. R., Reisi, P., & Ghanadian, M. (2024) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-024-00509-y · Cited by 8
“Thus, Acetylcholinesterase (AChE), tasked with ACh breakdown at postsynaptic junctions, emerges as a pivotal therapeutic target in AD’s pathogenesis, emphasizing its centrality in drug discovery [5].”
Genes related to neurotransmitter receptors as potential biomarkers for Alzheimer's disease
Chen, W., Zhang, T., & Zhang, H. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137816 · Cited by 8
Zhang, Y., Zhang, Y., Li, S., Liu, C., Liang, J., Nong, Y., Chen, M., & Sun, R. (2024) · Phytochemical Analysis · doi:10.1002/pca.3415 · Cited by 8
Ryu, M. S., Yu, Y., Li, C., Yang, H.-J., Zhang, T., Wu, X., Jeong, D., & Park, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117091 · Cited by 8
Mahadik, N., Barron, G. A., Lin, P. K. T., & Thompson, C. J. (2024) · Chemistry of Materials · doi:10.1021/acs.chemmater.4c01767 · Cited by 8
Olfactory deficits in aging and Alzheimer’s—spotlight on inhibitory interneurons
Elhabbari, K., Sireci, S., Rothermel, M., & Brunert, D. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1503069 · Cited by 8
“This reduction is well described in AD as well as in aging (Schliebs and Arendt, 2006; Sultzer, 2018; Chen et al., 2022).”
Bhratee, A., Chatterjee, D., Kaur, R., & Singh, S. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01579-w · Cited by 8
“This decline is associated with cholinergic degeneration observed in AD, where the ‘cho - linergic hypothesis’ is a key pathological hallmark (Chen et al. 2022 ).”
Said, M. F., Wadie, W., El-Haleim, E. A. A., El‐Shiekh, R. A., & El-Zoheiry, H. H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117720 · Cited by 8
Boualam, K., Scialla, S., Fasolino, I., Russo, T., Scarpa, E., Cesare, N. D., Guarino, V., Santis, R. D., Sobeh, M., Taarji, N., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144636 · Cited by 8
New and potential boron-containing compounds for treatment of Alzheimer's disease and cancers
Önder, F. C., Ural, K., Önder, A., Ozpolat, B., & Ay, M. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2525065 · Cited by 8
Ryu, H.-S., Sanjay, S., Choi, S.-K., Lee, K.-H., Jang, S.-S., Yang, S.-Y., Kwon, Y.-S., Ku, S., & Lee, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05223-7 · Cited by 8
Self-citationAvendaño-Godoy, J., Miranda, A., Sigrid Mennickent, C., & Gómez-Gaete, C. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.08.011 · Cited by 8
Zhang, R., He, X., Cheng, J., Zhang, X., Chen, H., Liu, Y., Chen, P., & Wang, Y. (2023) · Neurotoxicity Research · doi:10.1007/s12640-023-00677-w · Cited by 8
“Cholinergic system damage is another typical characteristic of AD (Hampel et al. 2018; Kumari et al. 2020), which is mainly manifested by upregulation of acetylcholinesterase (AChE), which degrades acetylcholine (ACh) (Chen et al. 2022; Singh and Gupta 2017).”
BackgroundGajowniczek-Ałasa, D., Szwajgier, D., & Baranowska‐Wójcik, E. (2024) · Current Alzheimer Research · doi:10.2174/0115672050306101240321050146 · Cited by 8
How calcineurin inhibitors affect cognition
Thiankhaw, K., Chattipakorn, N., & Chattipakorn, S. C. (2024) · Acta Physiologica · doi:10.1111/apha.14161 · Cited by 8
“35,36 Previous studies in human postmortem hippocampal tissue from aging and MCI subjects showed a concurrent elevation in calpain and calcineurin proteolytic fragment levels in the cytosolic fractions during MCI.”
BackgroundAttia, T. B., Horchani, M., Salhi, M., Ali, R. B., Jannet, H. B., Kacem, L. B. H., May, M. V. E., López‐Maldonado, E. A., & Mhamdi, A. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106489 · Cited by 8
Guo, Q., Wu, G., Huang, F., Wei, Z. C., Wang, J., Zhang, B., Liu, R., Yang, Y., Wang, X., & Li, H. (2022) · Aging · doi:10.18632/aging.204336 · Cited by 8
“Nevertheless, in recent years, therapies targeting at tau pathology, Aβ disposition or AChE turned out to be disappointing in clinical study [4, 5, 8].”
BackgroundThe RNA exosome maintains cellular RNA homeostasis by controlling transcript abundance in the brain
Higginson, L. A., Wang, X., He, K., Torstrick, M., Kim, M., Wijeratne, H. R. S., Runnebohm, A. M., Benayoun, B. A., MacLean, A., Chanfreau, G. F., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116729 · Cited by 7
“68–70 These findings highlight cholinergic dysregulation as an intriguing avenue for future investigation into how RNA exosome dysfunction perturbs neurotransmission.”
Alshammari, A. A. A., Arfeen, M., Alkhamiss, A. S., Alwesmi, M. B., & Mani, V. (2025) · Food and Chemical Toxicology · doi:10.1016/j.fct.2025.115448 · Cited by 7
Chen, J., Zhang, X., Sun, J., Zhi, Y., Xie, Z., Guan, Y., Zhang, Z., & Wu, C. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03709-z · Cited by 8
Padhy, D. S., Dhanve, P., Chaturvedi, K., & Banerjee, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178334 · Cited by 7
Marine-Derived Natural Substances with Anticholinesterase Activity
Dimitrova, D., Kehayova, G. K., Dimitrova, S., & Dragomanova, S. (2025) · Marine Drugs · doi:10.3390/md23110439 · Cited by 7
“A reduction in cholinergic neurotransmission can result in memory deficits and disorientation, which are commonly observed in AD and other neurodegenerative disorders [1].”
Recent synthetic strategies using MCRs for the discovery of pharmacologically active compounds
Sakthivel, K., & Singh, F. V. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2617611 · Cited by 7
Metadata
- Authors
- Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F.
- Affiliations
- Nanchang University (CN)
- Experimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China
- Corresponding author
- Yang, Shu-Long
- Hong, Fen-Fang
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 27
- Issue
- 6
- Pages
- 1816
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8949236
- OpenAlex
- W4220945110
- Cited by
- 922
- References
- 141
- Citations by year
- 2026: 256 · 2025: 347 · 2024: 202 · 2023: 87 · 2022: 29
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82060661, 81660751, 81660151)
- Jiangxi Provincial Natural Science Foundation of China (20212BAB206092)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic neurotransmission, acetylcholine, cholinergic hypothesis, cognitive decline, tau phosphorylation, neuroinflammation, apoptosis, Alzheimer's disease pathogenesis, Alzheimer's disease therapeutics
- MeSH terms
- Acetylcholine, Alzheimer Disease, Humans, Signal Transduction, Cholinergic Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.